HOME >> BIOLOGY >> NEWS
BEMA Fentanyl demonstrates substantial transmucosal delivery

Morrisville, North Carolina, May 7, 2007 -- BioDelivery Sciences International, Inc. (Nasdaq:BDSI) announced the results of a 12 subject, crossover study comparing the absorption of fentanyl from both single and multiple BEMA Fentanyl discs, as well as oral and intravenous doses of fentanyl. The data demonstrates that the absolute bioavailability (i.e. the total amount absorbed from the delivery system) of fentanyl through the BEMA disc was more than 70%, with 50% absorbed through the buccal mucosa (the inner lining of the cheek). The study further demonstrates that equal doses administered as either a single disc or multiple discs produced nearly identical plasma concentrations (i.e. two 200 mcg discs provided nearly equivalent plasma concentrations as one 400 mcg disc, etc.)

These findings follow the Companys April 25, 2007 announcement of statistically significant results with BEMA Fentanyl in treating cancer patients with breakthrough pain in the companys Phase III efficacy clinical trial. BDSI plans to include todays study results, the efficacy trial results and other materials in its planned submission of a New Drug Application (NDA) to the FDA for BEMA Fentanyl. The NDA submission is expected during third quarter of 2007.

BEMA Fentanyl consists of a small, dissolvable polymer disc, formulated with the opioid narcotic fentanyl, for application to the buccal membranes. Upon administration, BEMA Fentanyl is designed to deliver a rapid, reliable dose of drug across mucous membranes. BEMA Fentanyl is being developed for the treatment of "breakthrough" cancer pain (i.e. episodes of severe pain which "break through" the medication already in use to control the persistent pain).

Dr. Andrew Finn, Executive Vice President of Product Development for BDSI, stated "The results of this study confirm, and are an expansion of, the information obtained in our 2006 pharmacokinetic study which demonstrated that fentanyl absorption from th
'"/>

Contact: Bill Douglass
bill@investorrelationsgroup.com
BioDelivery Sciences
7-May-2007


Page: 1 2 3

Related biology news :

1. New study demonstrates important role of glia in circadian timing
2. Stowers Institutes Workman Lab demonstrates mechanism for decoding histone modification marks
3. Xie Lab demonstrates the role of microRNA pathway
4. Rong Li Lab demonstrates the process of mammalian egg maturation
5. Compelling evidence demonstrates that Hobbit fossil does not represent a new species of hominid
6. OHSU research demonstrates possible health risks for children born to overeating mothers
7. New research demonstrates bone-marrow derived stem cells can reverse genetic kidney disease
8. NYUS Childress demonstrates tool for studying hovering flight at international science meeting
9. Study demonstrates rapid diagnosis of urinary tract infections with biosensor technology
10. Report demonstrates safety of nuclear medicine procedures
11. New study shows Emezine demonstrates more efficient absorption

Post Your Comments:
(Date:5/21/2013)... world,s largest scientific society, invites news media coverage ... 8-12, 2013, in Indianapolis, Ind. It will take ... area hotels. , With more than 7,100 presentations ... from astronomy to zoology ― the meeting will ... assortment of spot news and feature possibilities. The ...
(Date:5/21/2013)... the path of insulin action in cells in precise ... for understanding what goes wrong in diabetes. , ... David James from Sydney,s Garvan Institute of Medical Research, ... the prestigious journal Cell Metabolism . , First ... important role in the body because it helps us ...
(Date:5/20/2013)... Bacteria resistant to the antibiotic colistin are also ... human body, according to a study in ... American Society for Microbiology. Cross-resistance to colistin and ... the body against bacterial attack, could mean that ... saddled with a crippled immune response. Colistin is ...
Breaking Biology News(10 mins):Insight into the dazzling impact of insulin in cells 2Insight into the dazzling impact of insulin in cells 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/22/2013)... CAMBRIDGE, Mass. , May 22, 2013  Moderna ... revolutionary new treatment modality to enable the in ... John Reynders will join Moderna ... Reynders is a proven leader in ... phases of drug development, from discovery to translation, clinical ...
(Date:5/21/2013)... May 21, 2013  The Lindsley F. Kimball Research Institute ... is a Grand Challenges Explorations winner, an initiative ... Dr. Sara Lustigman , Head of the ... and development research project, titled Innovative 3-D in ... are needed to screen drugs to help eliminate onchocerciasis (river ...
(Date:5/21/2013)... a new study led by George Washington University ... nucleation of ice in small droplets is strongly ... at the nanoscale. The formation of ice at ... question whose answer also has important implications for ... crystallization of ice from supercooled water is generally ...
(Date:5/21/2013)... Branchburg, NJ (PRWEB) May 21, 2013 ... enhancement industry, has appointed Dale Braddy to Southeastern USA ... proactively bolster its sales muscle in the Southeast. ... a food ingredient brokerage and supplier to food processors ... past 13 years in the food industry and has ...
Breaking Biology Technology:Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2
Cached News: